Bridging discovery to first-in-human: Overcoming translational bottlenecks for new oligonucleotide drug classes
30 Apr 2026
Novel Modalities & Discovery
- How can early discovery teams better predict human translation for novel backbone chemistries and conjugation strategies?
- What preclinical models are most informative for de risking first in human studies for emerging oligonucleotide classes
- How should developability and safety considerations be integrated earlier into discovery decision-making
- What data packages are regulators expecting to see for first-in-human entry with non-traditional oligonucleotide modalities
- How can discovery and translational teams align on go/no-go criteria to avoid late-stage attrition